Systemic Therapy in Patients with LA-SCCHN: Future Directions
Learning Objectives
Upon completion of this program, participants will be able to:
- Recognize the need for novel therapeutic approaches for LA-SCCHN
- Summarize the main findings of recent major trials in LA-SCCHN
- Identify phase 3 trials for LA-SCCHN anticipating results within the upcoming two years
Speakers
Dr. Denis Soulières
Course
This is a 60-minute MOC accredited program for Canadian Oncologists and other health care professionals. The goal is to raise awareness of head and neck cancers among Canadian Oncologists, with a focus on unmet needs in locally-advanced squamous cell carcinoma of the head and neck (LA-SCCHN), and agents under investigation.
Accreditation
This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University Office of CPD. You may claim a maximum of 0.75 hours (credits are automatically calculated.
This program has been made possible through unrestricted support from EMD Serono.
Studies/trials discussed:
- JAVELIN Head and Neck 100 study
- JAVELIN Head and Neck 100 phase 3 trial
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- KEYNOTE-412 trial
- NRG-HN004 trial
- REACH trial
- LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial
- KEYNOTE-689 trial
- Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation
- Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial
- TrilynX study
- Trilynx: A Phase 3 Trial of Xevinapant and Concurrent Chemoradiotherapy (CRT) for Locally Advanced Head and Neck Cancer
- XRay Vision study
- XRay Vision: A phase 3 study of xevinapant plus radiotherapy (RT) for high-risk, cisplatin-ineligible patients with resected, locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)
- Protocol 09PRT/5612:Phase III, double-blind, placebo-controlled study of postoperative adjuvant concurrent chemoradiotherapy with or without nimotuzumab for stage III/IV head and neck squamous-cell cancer (IHN01)
- IHN01 study
- A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003
